Radiation plus immunotherapy shows promise in bile duct cancer trial
NCT ID NCT07638501
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to receive either the standard treatment or the standard treatment plus radiation. The goal is to see if the combination is more effective and safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eastern Hepatobiliary Surgery Hospital
Shanghai, 201805, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A new test could reveal how radiation affects the liver
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?